AU2016215173B2 - Compositions and methods for treatment of edema - Google Patents

Compositions and methods for treatment of edema Download PDF

Info

Publication number
AU2016215173B2
AU2016215173B2 AU2016215173A AU2016215173A AU2016215173B2 AU 2016215173 B2 AU2016215173 B2 AU 2016215173B2 AU 2016215173 A AU2016215173 A AU 2016215173A AU 2016215173 A AU2016215173 A AU 2016215173A AU 2016215173 B2 AU2016215173 B2 AU 2016215173B2
Authority
AU
Australia
Prior art keywords
lymphatic
tacrolimus
treatment
lymphedema
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215173A
Other languages
English (en)
Other versions
AU2016215173A1 (en
Inventor
Omer Aras
Jason GARDENIER
Babak MEHRARA
Ira SAVETSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2016215173A1 publication Critical patent/AU2016215173A1/en
Application granted granted Critical
Publication of AU2016215173B2 publication Critical patent/AU2016215173B2/en
Priority to AU2020201161A priority Critical patent/AU2020201161B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2016215173A 2015-02-05 2016-02-05 Compositions and methods for treatment of edema Active AU2016215173B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201161A AU2020201161B2 (en) 2015-02-05 2020-02-18 Compositions and methods for treatment of edema

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112273P 2015-02-05 2015-02-05
US62/112,273 2015-02-05
PCT/US2016/016680 WO2016127013A1 (en) 2015-02-05 2016-02-05 Compositions and methods for treatment of edema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201161A Division AU2020201161B2 (en) 2015-02-05 2020-02-18 Compositions and methods for treatment of edema

Publications (2)

Publication Number Publication Date
AU2016215173A1 AU2016215173A1 (en) 2017-08-24
AU2016215173B2 true AU2016215173B2 (en) 2019-11-21

Family

ID=56564721

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016215173A Active AU2016215173B2 (en) 2015-02-05 2016-02-05 Compositions and methods for treatment of edema
AU2020201161A Active AU2020201161B2 (en) 2015-02-05 2020-02-18 Compositions and methods for treatment of edema

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201161A Active AU2020201161B2 (en) 2015-02-05 2020-02-18 Compositions and methods for treatment of edema

Country Status (9)

Country Link
US (5) US10251871B2 (enExample)
EP (1) EP3253211B1 (enExample)
JP (2) JP6704403B2 (enExample)
CN (2) CN114588154A (enExample)
AU (2) AU2016215173B2 (enExample)
CA (1) CA2975879A1 (enExample)
ES (1) ES3040783T3 (enExample)
HK (1) HK1247789A1 (enExample)
WO (1) WO2016127013A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1247789A1 (zh) * 2015-02-05 2018-10-05 Memorial Sloan Kettering Cancer Center 用於治疗水肿的组合物和方法
EP3500308A4 (en) * 2016-08-18 2020-04-22 Memorial Sloan Kettering Cancer Center INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES
MX2021002916A (es) * 2018-09-14 2021-08-24 Puretech Lyt 100 Inc Pirfenidona enriquecida con deuterio y métodos para su uso.
EP3876905A4 (en) * 2018-11-05 2022-08-03 Apramitha Innovations Private Limited Teriflunomide topical pharmaceutical compositions
WO2021186401A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
CN112642065B (zh) * 2020-12-28 2022-08-02 锐可医疗科技(上海)有限公司 激光治疗仪及存储介质
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20080009536A1 (en) * 2002-08-10 2008-01-10 Pershadsingh Harrihar A Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20120130144A1 (en) * 2009-02-04 2012-05-24 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011669A1 (ja) * 2003-08-05 2005-02-10 Dainippon Sumitomo Pharma Co., Ltd. 経皮投与用医薬組成物
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
CN101443004B (zh) * 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
EP2036555B1 (en) * 2006-06-15 2011-11-16 Shanghai Genomics, Inc. The use of pyridone derivatives for preventing and treating radiation injury of lungs
CA2823407C (en) * 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
HK1247789A1 (zh) * 2015-02-05 2018-10-05 Memorial Sloan Kettering Cancer Center 用於治疗水肿的组合物和方法
US10292961B2 (en) * 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20080009536A1 (en) * 2002-08-10 2008-01-10 Pershadsingh Harrihar A Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20120130144A1 (en) * 2009-02-04 2012-05-24 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOEHM M; RIEMANN B; LUGER T A; BONSMANN G, "Bilateral upper limb lymphoedema associated with psoriatic arthritis: A case report and review of the literature", BRITISH JOURNAL OF DERMATOLOGY, (2000-12-01), vol. 143, no. 6, pages 1297 - 1301 *
GARNY DE LA RIVIÈRE C ET AL, "Lymphoedème génital associé à une maladie de Crohn", REVUE DE MEDECINE INTERNE, (2014-02-25), vol. 36, no. 4, doi:10.1016/J.REVMED.2014.01.006, ISSN 0248-8663, pages 291 - 293 *
HARIKRISHNA MAKANI; SRIPAL BANGALORE; JORGE ROMERO; OMAR WEVER-PINZON; FRANZ H. MESSERLI;: "Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema", AMERICAN JOURNAL OF MEDICINE., EXCERPTA MEDICA, INC., UNITED STATES, vol. 124, no. 2, 1 February 2011 (2011-02-01), United States, pages 128 - 135, XP028136579, ISSN: 0002-9343, DOI: 10.1016/j.amjmed.2010.08.007 *
Lopez et al, "Penile and scrotal edema as a manifestation of Crohn's disease", International Journal of Dermatology (2009), Vol 48, No 10, Pages 1136-1137, DOI: 10.1111/j.1365-4632.2008.03751.x *
ROMAGNOLI J ET AL, "Severe Limb Lymphedema in Sirolimus-Treated Patients", TRANSPLANTATION PROCEEDINGS, ELSEVIER INC, ORLANDO, FL; US, vol. 37, no. 2, ISSN 0041-1345, (2005-03-01), pages 834 - 836, (2005-03-01) *
RUZICKA, THOMAS et al., "A short-term trial of tacrolimus ointment for atopic dermatitis.", New England Journal of Medicine, (1997), vol. 337, no. 12, pages 816 - 821 *
TAKANORI YAMAZAKI, YAMASHITA NAOTO, IZUMI YASUKATSU, NAKAMURA YASUHIRO, SHIOTA MASAYUKI, HANATANI AKIHISA, SHIMADA KENEI, MURO TAK: "The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice", HYPERTENSION RESEARCH. CLINICAL AND EXPERIMENTAL., OSAKA., JP, vol. 35, 1 January 2012 (2012-01-01), JP, pages 34 - 40, XP055470544, ISSN: 0916-9636, DOI: 10.1038/hr.2011.139 *
U.S. National Library of Medicine, "Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema", (2014-08-26), ClinicalTrials.gov, URL: https://www.clinicaltrials.gov/ct2/show/NCT00826618?term=cyclosporin&cond=edema&rank=1 *

Also Published As

Publication number Publication date
CN107427007A (zh) 2017-12-01
US20230241043A1 (en) 2023-08-03
ES3040783T3 (en) 2025-11-04
JP6926263B2 (ja) 2021-08-25
AU2020201161B2 (en) 2021-07-15
JP2020114830A (ja) 2020-07-30
CN114588154A (zh) 2022-06-07
WO2016127013A1 (en) 2016-08-11
US10251871B2 (en) 2019-04-09
US20250235436A1 (en) 2025-07-24
HK1247789A1 (zh) 2018-10-05
EP3253211A1 (en) 2017-12-13
CN107427007B (zh) 2022-02-11
CA2975879A1 (en) 2016-08-11
EP3253211A4 (en) 2018-10-31
AU2020201161A1 (en) 2020-03-05
US12144805B2 (en) 2024-11-19
EP3253211B1 (en) 2025-06-11
JP2018504436A (ja) 2018-02-15
JP6704403B2 (ja) 2020-06-03
US20210069164A1 (en) 2021-03-11
AU2016215173A1 (en) 2017-08-24
US20180028514A1 (en) 2018-02-01
US20200016137A1 (en) 2020-01-16
US11583523B2 (en) 2023-02-21
US10874651B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
US12144805B2 (en) Compositions and methods for treatment of edema
Gardenier et al. Topical tacrolimus for the treatment of secondary lymphedema
Yu et al. Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect
CA3033863C (en) Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
JP6941565B2 (ja) がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
Brown et al. Topical captopril: A promising treatment for secondary lymphedema
JP2019522658A (ja) 線維症の治療に使用するためのＷｎｔ阻害剤
EP4132954A1 (en) Use of cdon inhibitors for the treatment of endothelial dysfunction
AU2023202294A1 (en) Compositions and methods for immune-mediated cancer therapy
US20230056301A1 (en) Compositions and methods for delivering therapeutic antibodies using platelet-derived microparticles
US20240117052A1 (en) Antibody for cancer treatment conjugated to tumor environment-sensitive traceless-cleavable polyethylene glycol and manufacturing method thereof
KR101277873B1 (ko) Ｎｉｎｊｕｒｉｎ 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물
US20200330459A1 (en) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
Fukumura Tumor Microcirculation: Abnormalities and Normalization
WO2024059336A1 (en) Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)